Management of diverticular disease: Is there room for rifaximin?

被引：14

作者：

Papi, C ^{[1
]}

Koch, M ^{[1
]}

Capurso, L ^{[1
]}

机构：

[1] S Filippo Neri Hosp, Dept Gastroenterol & Internal Med, Unita Operat Gastroenterol, IT-00135 Rome, Italy

来源：

CHEMOTHERAPY | 2005年 / 51卷

关键词：

diverticular disease; diverticulitis; antibiotics; rifaximin;

D O I：

10.1159/000081997

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment of symptomatic diverticular disease of the colon is aimed at the relief of symptoms and the prevention of major complications. The efficacy of fiber supplementation and of anticholinergic and spasmolytic agents remains controversial. Antibiotics are commonly used in the treatment of inflammatory complications of diverticular disease. Data from open labelled and randomized controlled trials do suggest the efficacy of rifaximin in obtaining symptomatic relief in patients with diverticular disease. Approximately 30% therapeutic gain compared to fiber supplementation only can be expected after one year of intermittent treatment with rifaximin. Considering the safety and tolerability of rifaximin, this drug can be recommended for patients with symptomatic uncomplicated diverticular disease. Copyright (C) 2005 S. Karger AG, Basel.

引用

页码：110 / 114

页数：5

共 49 条

[41] MECHANISM OF ACTION OF DIETARY FIBER IN THE HUMAN-COLON [J].